Holen Sie sich die Stockscreener-App
2.03
0.98%
-0.02
Vorhandelsmarkt:
2.05
0.02
+0.99%
Actuate Therapeutics Inc Aktie (ACTU) Neueste Nachrichten
Actuate Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
ACTU Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Advances PipelineEarnings Revision Upgrade - newsline.com
Buy Rating Reaffirmed on Elraglusib Momentum and External Validation; $15 ACTU Price Target Maintained - TipRanks
H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion - Investing.com
H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Actuate’s elraglusib to be evaluated in BEACON2 neuroblastoma trial - Investing.com
Actuate Therapeutics to Evaluate Elraglusib in BEACON2 Clinical Trial for Relapsed Neuroblastoma in Partnership with Cancer Research UK Clinical Trials Unit - Quiver Quantitative
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma - GlobeNewswire
Actuate Therapeutics (ACTU) Surges 6.59% as Biotech Momentum Builds Above Key SupportSystematic Flow - newsline.com
Elraglusib shows significant survival benefits in metastatic pancreatic cancer combined with standard chemo. - Pluang
Actuate presents elraglusib trial data at ASCO meeting By Investing.com - Investing.com South Africa
Actuate presents elraglusib trial data at ASCO meeting - Investing.com
Actuate Therapeutics Reports Positive Survival Outcomes for Elraglusib in Combination with Standard Chemotherapies for Metastatic Pancreatic Ductal Adenocarcinoma at ASCO 2026 - Quiver Quantitative
Actuate Therapeutics Announces ASCO Poster Presentations - GlobeNewswire
Actuate Therapeutics (ACTU) Declines 2.88% as Stock Nears Key Support ZoneEarnings Beat Stocks - The Legal Advocate
Actuate Therapeutics (ACTU) Holds Near Support Amid Low VolatilityVolume Spike Alerts - The Legal Advocate
Actuate Therapeutics (ACTU) Drops 4.09% as Shares Test Critical $2.00 Support LevelFlat Correction - newsline.com
ACTU Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseGuidance vs Actual - Newser
Actuate Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com - Investing.com India
Actuate Therapeutics, Inc. Files Form 8-K Current Report with SEC Detailing Company Information and Nasdaq Listing - Minichart
Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor - TipRanks
Actuate Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com
Actuate Therapeutics, Inc.Common stock (NQ: ACTU - The Chronicle-Journal
Actuate Therapeutics (ACTU) Holds Near Support After Modest UptickCrowd Breakout Signals - Newser
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail
ACTU Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus
Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co. - Moomoo
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Actuate Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Actuate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Analysts Are Bullish on These Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Agios Pharma (AGIO) - The Globe and Mail
Actuate Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Craig-Hallum Remains a Buy on Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail
TradingKey - TradingKey
Craig-Hallum Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
Actuate Wins FDA Clearance for Oral Elraglusib Trial - TipRanks
Actuate Therapeutics (NASDAQ: ACTU) gets FDA IND ok but flags cash risk - Stock Titan
Actuate Therapeutics Announces FDA Clearance of IND for - GlobeNewswire
Actuate Therapeutics Adds Oncology Expert to Board Leadership - TipRanks
Actuate Therapeutics Adds Oncology Veteran Martin Huber to Board as Elraglusib Advances - citybiz
Actuate Therapeutics appoints Martin Huber to board - Investing.com
Actuate Therapeutics appoints Martin Huber to board By Investing.com - Investing.com Australia
Actuate Therapeutics Appoints Dr. Martin Huber as Independent Director to Strengthen Leadership Team - Quiver Quantitative
Cancer drug developer Actuate taps ex-Mersana CEO for board seat - Stock Titan
Actuate Therapeutics, Inc. Announces Appointment of Martin Huber as an Independent Director, Effective May 6, 2026 - marketscreener.com
Actuate Therapeutics (ACTU) price target decreased by 17.00% to 21.16 - MSN
Short Interest in Actuate Therapeutics, Inc. (NASDAQ:ACTU) Grows By 40.1% - MarketBeat
Actuate Therapeutics announces public offering of common stock - MSN
Why did Actuate Therapeutics (ACTU) stock jump over 14% after hours? - MSN
Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - whbl.com
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):